✨ Free AI Report
Eli Lilly and Company: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Eli Lilly and Company
Company Research

Eli Lilly and Company: Business Overview, Financials & Competitive Analysis

Eli Lilly has entered the trillion-dollar market cap club, projecting record 2026 revenue of $80-$83 billion driven by insatiable global demand for its dual-agonist metabolic treatments, Mounjaro and Zepbound. This re...

Analyst-debate audio for Eli Lilly and Company

AskCyborg analysts argue the bull and bear cases for Eli Lilly and Company across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
9/ 10Exceptional

Cyborg Score thesis

Unmatched manufacturing scale combined with blockbuster GLP-1 franchise positions Eli Lilly for sustained hypergrowth in the...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Pharmaceutical Manufacturing & Distribution
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Eli Lilly and Company Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Eli Lilly and Company Overview

Pro stress-test →

Eli Lilly has entered the trillion-dollar market cap club, projecting record 2026 revenue of $80-$83 billion driven by insatiable global demand for its dual-agonist metabolic treatments, Mounjaro and Zepbound. This represents a staggering 25% year-over-year growth, signaling that the obesity and diabetes market is still in its early innings of expansion.

Strategic Profile

Pro stress-test →

By controlling both the clinical development and the massive manufacturing infrastructure required to deliver metabolic treatments, Lilly has built a business model that is currently unrivaled in the industry. The company leverages its first-mover advantage and superior manufacturing scale to command over 60% of the metabolic health market share, with a multi-modal portfolio ranging from injectable tirzepatide to oral pills and the upcoming triple-agonist retatrutide.

Competitive Landscape

Pro stress-test →

Novo Nordisk has emerged as a temporary loser, projecting a 5-13% decline in 2026 sales due to intense pricing competition and production bottlenecks. Eli Lilly's superior manufacturing scale, diverse portfolio, and first-mover advantage in the GLP-1 space create significant competitive barriers. Other key competitors include Merck and AstraZeneca in diabetes/obesity segments.

Industry Context

Eli Lilly and Company operates in Biopharmaceutical/Pharmaceutical Manufacturing & Distribution.

Key facts

Founded: 1876 · Headquarters: Indianapolis, US · Employees: N/A · Revenue: $59.4B (TTM) · Market cap: $975B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Eli Lilly and Company.

  • Mounjaro grew 110% to $7.4 billion and Zepbound grew 123% to $4.3 billion in Q4 2025, with combined sales representing over 60% of company revenue.
  • Mid-2026 launch of orforglipron, Lilly's daily obesity pill, could eliminate the need for injections for millions of patients.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Issued blockbuster financial guidance projecting 2026 revenue of $80-$83 billion, entering the trillion-dollar club.
  • February 2026Stock surged 10% following guidance announcement, solidifying position as world's most valuable healthcare company.
  • +2 moreTrack every material event for Eli Lilly and Company as it happens. Explore monitoring →
Get alerted when Eli Lilly and Company has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ozempic/WegovyCompetitor GLP-1 diabetes and obesity treatments→KeytrudaLeading cancer immunotherapy→Diabetes/Obesity PortfolioEmerging competitor in metabolic health→

Compare Eli Lilly and Company with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Eli Lilly and Company operates in Biopharmaceutical/Pharmaceutical Manufacturing & Distribution. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Pharmaceutical Manufacturing & Distribution research →
NEW · MCP server

Ask your AI assistant about Eli Lilly and Company

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Eli Lilly and Company and its top competitor on Cyborg Score”
“What did Eli Lilly and Company do this quarter?”
“Is Eli Lilly and Company a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Eli Lilly and Company do?+
Eli Lilly has entered the trillion-dollar market cap club, projecting record 2026 revenue of $80-$83 billion driven by insatiable global demand for its dual-agonist metabolic treatments, Mounjaro and Zepbound. This re...
What is Eli Lilly and Company's Cyborg Score?+
Eli Lilly and Company has a Cyborg Score of 9/10 (Exceptional). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Eli Lilly and Company's main competitors?+
Named competitors include Ozempic/Wegovy, Keytruda, Diabetes/Obesity Portfolio. The full competitive landscape is in the AskCyborg report.
How can I get the full Eli Lilly and Company research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Eli Lilly and Company research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Eli Lilly and Company over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score